secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001178913-22-003055
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio reports Q2 results: submits EB613 protocol to FDA, net loss $7.0M, cash $17.3M
--------------------------------------------------------------------------------

- Submitted proposed registrational protocol for EB613 (oral PTH) to FDA; expects Type C meeting in H2 2022.
- Finalizing optimized formulation for EB612 (hypoparathyroidism); first-in-human PK study planned H1 2023.
- Net loss $7.0M ($0.24 per share) for six months ended June 30, 2022, vs $4.9M ($0.21) in prior year period.
- Revenue $112k, down from $226k; operating expenses $7.1M, up from $5.0M.
- Cash $17.3M as of June 30, 2022, expected to fund operations through Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891322003055/0001178913-22-003055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891322003055/zk2228294.htm
  HTML page:      https://secwatch.observer/filing/0001178913-22-003055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer